CALGARY, AB, Jan. 7, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”) has been granted a No Objection Letter (“NOL”) by Health Canada, a crucial step towards opening ATMA’s first sponsored clinical trial. The trial participants are licensed health care providers enrolled in a psychedelic-assisted therapy program. The trial’s primary goal will be to document the safety of synthetic psilocybin when administered to healthy participants in a controlled clinical setting. The secondary exploratory approach of the trial will be to assess the psychological outcome, documented by self-administered assessments before and after the experiential psilocybin session.

The trial will begin in mid-2022, led by psychiatrist and Chief Medical Officer of ATMA: Dr. Ravinder Bains. “Health care providers who meet our inclusion criteria will enrol in the trial after careful screening and assessment,” states Dr. Bains. “Further, after administration of psilocybin during the experiential session, we will be documenting heart rate, body temperature, blood pressure, and monitoring for irregular heartbeat via ECG.” Dr. Bains has stated that he does not expect any long-term or serious adverse events based on published literature. Still, it will be essential to acquire this primary safety data with healthy individuals as a baseline for future studies with psilocybin. “There is a growing body of evidence in reputable medical journals that psychedelic medicine, and specifically psilocybin, has very significant efficacy in treating a variety of mental health issues. We [ATMA] believe this approach will offer much hope to patients suffering from mental health issues that have been untreatable, but believe it is crucial to begin this journey to treatment with basic safety data.”

In addition to demonstrating the safety of psilocybin in a clinical setting, study investigators and participants will gain a greater appreciation of the effects and intended therapeutic applications of the medicine via psychological assessments. Once enrolled, participants will complete self-administered basic assessments of psychological well-being, which will then be repeated two days after their experiential session. “These exploratory assessments of the trial will allow us to compile additional data regarding the psychological outcome of psilocybin treatment in healthy individuals,” continues Dr. Bains. “The fact that the participants are health care providers that deal daily with patients with serious mental health issues will provide a unique first-hand perspective on the potential of psychedelic-assisted therapy.”

The regulatory environment surrounding psychedelic medicine in Canada has become increasingly receptive to progression, as evidenced by recent amendments to the Special Access Program, released January 4, 2022, allowing physicians to request psychedelic medicine on behalf of eligible patients. With sufficient clinical and scientific evidence, together with the NOL granted to ATMA, Canadian policymakers and healthcare professionals are receptive to the therapeutic potential of psychedelic medicine.

“With the studies that have already been done, and based on increasing clinical evidence, the future of psychedelic medicine is becoming a reality as a viable therapy,” states David Harder, co-CEO of ATMA. “While the access of psychedelic medicine for patients will continue to be something we all work towards, we are optimistic that with ongoing research and clinical trials, 2022 is going to be a banner year in seeing these novel and effective treatment options become an important tool of therapy for many therapists and medical professionals.”

ATMA is a Canadian company focused on delivering practical and innovative healing and transformative experiences that leverage the potential of psychedelic medicine to awaken the inner healer and allow a deeper connection with self, with others, and with the beauty of our world. ATMA was the first private company in Canada to conduct legal psychedelic-assisted therapy with psilocybin, one of the active hallucinogens found in ‘magic mushrooms. For more information, visit

For further information: MEDIA CONTACT: David Harder, Co-CEO, ATMA Journey Centers Inc.,

More News and Media:

Breaking Through the Stigma

By David Harder, ATMA co-founder and co-CEO I met with a gentleman – a pastor of sorts – from my former religious life. We sat down to enjoy a pint and a burger at a local watering hole. It had been many years since we had last spoken, simply due to the chaos of life,

How To Change Your Mind

Upon the release of his book How to Change Your Mind, Michael Pollan sparked a major shift in the mindset of numerous therapists and medical professionals, as well as the general public. At the time of its publication in the spring of 2019, discussions surrounding psychedelics were happening, but in small, hushed groups of underground

Clinical Trials and Psychedelics

Clinical trials are the standard way to evaluate the safety and efficacy of new drugs (including psychedelic drugs) for medical use. Clinical trials also serve to test novel treatment options, explore ways to improve quality of life for people living with illnesses or diseases, and assess whether a new drug or treatment has fewer side

Psilocybin-assisted Therapy: The Safe and Effective Alternative

Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various mental health conditions. However, many healthcare professionals may be hesitant to use this type of treatment with their patients because of the misconception that psychedelics are dangerous and unsafe. This blog post will share evidence of the safety of psilocybin as an effective treatment option

Magic Mushroom - ATMA

Magic Mushrooms (Psilocybin) and End-of-life

End-of-life distress has been an ongoing focus for psilocybin clinical trials, as psilocybin has the potential to offer relief for existential distress when other forms of treatment fail. Health Canada has granted access to psilocybin through the Section 56 Exemption program, which is a patient led application requesting access to psilocybin. These exemptions are reviewed

Is Training in Psychedelics Worth It?

Let’s start with a brief review of psychedelics, including what they are and how they differ from conventional Western medicine. There are many substances under the umbrella of psychedelics; the common ones are: Psilocybin (the active ingredient in magic mushrooms)  LSD (lysergic acid diethylamide) Ibogaine (the active ingredient in iboga) Mescaline (the active ingredient in

ATMA Submits Phase II Clinical Trial Application, Assessing Psilocybin Efficacy in Healthcare Professionals Suffering From COVID-19-Related Mental Wellness Challenges.

CALGARY, AB, May 10, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of its innovative psychedelic-assisted therapy solutions, announced the submission of its N-500 Phase II Psilocybin Clinical Trial to Health Canada today. This trial is aimed at studying the potential relief of COVID-19-associated mental health concerns in healthcare professionals, as well

Scroll to Top